Fred Alger Management, LLC Arcus Biosciences, Inc. Transaction History

Fred Alger Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$14.83 - $20.18 $25,047 - $34,084	-1,689 Reduced 2.25%	73,498 $1.39 Million
Q4 2023 Feb 14, 2024	SELL	$13.43 - $19.63 $10,488 - $15,331	-781 Reduced 1.03%	75,187 $1.44 Million
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $405 - $541	-23 Reduced 0.03%	75,968 $1.36 Million
Q2 2023 Aug 14, 2023	SELL	$16.97 - $22.03 $32,582 - $42,297	-1,920 Reduced 2.46%	75,991 $1.54 Million
Q1 2023 May 15, 2023	SELL	$15.96 - $23.15 $9.15 Million - $13.3 Million	-573,601 Reduced 88.04%	77,911 $1.42 Million
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $12.8 Million - $23.3 Million	651,512 New	651,512 $13.5 Million

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.